Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IMO...going to need a partnership.
Last I heard he was touring private islands in the Maldives planning his retirement.
Health Canada approval caused a 5 fold increase in price from the open to the high. Wait to see what FDA approval will do.
Dear Stakeholder;
Attached is the press release about our FDA filing and here is some background.
1. We are our own predicate device which means since we are approved for RV analysis, the FDA compares our current updated device (all 4 chambers) to our existing device (RV only). Of course the devices are identical since all we have changed is the databases, which are used to determine the volumes and ejection for each chamber of the heart.
2. We use the same artificial intelligence approach for all the chambers so the actual workings of the VMS+ device have not changed and so all the previous reviews by the FDA about how the device works and its safety are valid.
3. This means the FDA has very little to do except look at the mean and the variance for all three measured parameters volume at start of the heart beat, volume at the end of the hearts beat and the ejection fraction for the additional 3 chambers (LA.RA,LV) so 2x3x3 or 18 numbers and these all show equivalency (within +/-10%) to MRI. We still used the MRI as the reference determination for each hear analyzed.
4. Previously the FDA has been concerned we do hearts form many different heart conditions (CHD, PAH, congestive heart failure, MI, ischemic heart failure, etc.) so we did all of these and many more so they can have confidence the VMS+ can analyze any heart.
5. Last time we applied to go from PAH to all hearts for RV analysis it took them 42 days to approve the application, so we are hopeful this one will be equally as quick, but you never know with the FDA.
6. We know the application is complete as it has passed administrative review and so is actively being reviewed for content.
As usual, if you have questions send me an email or call.
Thanks for your continue support.
Regards,
George Adams, PhD, ICD.D
CEO
Ventripoint Diagnostics Ltd..
Cell: 519-803-6937
TSXV: VPT
Read more at http://www.stockhouse.com/companies/bullboard#Jf3yudyB49rAtZM0.99
I'm on board..picked em up today
This looks really good
GL
Their international patent gives them 30 months from their priority date filed in 3/16. I believe this gives them until August to have a device.
Great post as always shell. Spot on as usual.
I know for me the biggest tipping point was the addition of Dr. Huestis. I asked myself why would this highly respected, lifelong leader in her field just walk way from a top position government job to join Cannabix?
After a little DD I quickly realized this woman's passion and commitment to solve the issue of drugged driving. It looked to me like her decision was furthering her mission and continuing her legacy of making a major difference and saving lives. At this point I went all in.
I'm very motivated as to actually see that it changes things like reducing deaths from drugged driving...
We believe we can be court certified within 9-12 months which will hopefully coincide with legalization in Canada.
My guess is Ahmadi spent some time with Dr. David Hasman.
Ahmadi, the course instructor, came to UPEI from the University of British Columbia.
While a graduate student at UBC, he worked with a couple of his supervisors, who are also leading experts in developing handheld breathalyzers.
After a career at Hewlett-Packard and Agilent Technologies Dr. Hasman taught chromatographic based analysis at BCIT and University of British Columbia.
Cannabix unaware of any material change
10:36 am ET December 28, 2017 (Globe Newswire) Print
Cannabix Technologies Inc. (CSE:BLO) (the "Company") reports at the request of IIROC (Investment Industry Regulatory Organization of Canada), Cannabix wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity.
About Cannabix
Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC - the psychoactive component of marijuana that causes intoxication - using breath samples. In Particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects use days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous.
On behalf of the Board of Directors of Cannabix
Rav Mlait
Great find!!
My favorite part...
They also say it might not be prudent to take the device to market as a startup, especially since Cannabix is already in clinical trials for a device that could be used roadside by law enforcement.
Yes, the link I posted was two years old. I referenced it to connect Lovrich to Dr Hill's group, for your benefit.
My take is...yeah what shell said.
I completely agree its a terrible idea. However I found his comment about breath testing very interesting. He is part of Dr Herbert Hill group at WSU working on a similar breathalyzer.
And the breath test? So-so. He says it would be very expensive to refine that technology for police use.
Question???
When the FAIMS device is completed how much $$$$ will be needed to get it through trials and FDA approval? How large of a PP will be needed to fund the device until completion?
IMO - I just don't see them ever raising enough cash through PP to bring it to market and Yost knows it. IMO - I can see them being sold to a big fish with deep pockets who can see this to the end.
Pittcon 2018
FAIMS-MS Strategies for Separating Drug Isomers
205B
850-7
10:25am - 10:45am
Tue, Feb 27
Wei, Michael - University of Florida
Co-authors: Kemperman, Robin H - University of Florida, Yost, Richard A - University of Florida
High-field asymmetric-waveform ion mobility spectrometry (FAIMS) is an emerging technology that has great potential for targeted applications. FAIMS utilizes an alternating asymmetric electric field to separate ions by their different mobilities at high- and low-fields as they travel through the separation space. When coupled to mass spectrometry, FAIMS enhances the separation of analytes from other interfering compounds with little to no increase in analysis time. Several strategies have been investigated to improve the FAIMS separation for small isomeric molecules. These strategies include adding solvent vapor to the FAIMS cell and using various cations to form ion complexes that enhance ion mobility differences between isomers.
In this work, we utilize these strategies to separate isomers for two groups of drugs: anabolic androgenic steroids and opioids. The use of anabolic steroids as performance enhancing substances is prohibited in sporting events by the World Anti-Doping Agency, leading some athletes to use designer steroids to evade detection. Opioid addiction is an escalating problem that is compounded by the introduction of synthetic opiate analogues such as fentanyl. Screening methods for both of these compound classes are being challenged by the availability of synthetically manufactured analogues, including isomers of existing substances.
Solvent vapor addition has been demonstrated to dramatically improve analyte separation in FAIMS-MS. When dry nitrogen gas is used in the FAIMS cell, the FAIMS peaks for the [M+H]+ ions of morphine and norcodeine cannot be resolved (m/z 286). However, when a mixture of nitrogen gas and acetonitrile vapor is used, morphine is baseline resolved from norcodeine. Cation addition can produce ion adducts for specific isomers that result in unique FAIMS peaks. For example, the [2M+K]+ ion for testosterone (m/z 615) results in two peaks, with one peak that is fully separated from the single peak of epitestosterone.
Cannabix Technologies Inc. Announces $3.45 Million Bought Deal Private Placement
November 17, 2017
Vancouver, British Columbia, November 17, 2017 -- Cannabix Technologies Inc. (CSE: BLO) (the “Company or Cannabix”) is pleased to announce that it has entered into an agreement with Cormark Securities Inc. (the “Underwriter”) pursuant to which the Underwriter has agreed to purchase 3,000,000 units (“Units”) of the Company on a bought deal private placement basis at a price of $1.15 per Unit (the “Offering Price”), for gross proceeds of $3.45 million (the “Offering”). Each Unit shall consist of one common share (a “Common Share”) of the Company and one common share purchase warrant. Each warrant will entitle the holder thereof to purchase one Common Share at a price equal to $1.60 for a period of 36 months following Closing.
In addition, the Company has granted the Underwriter an option to purchase up to an additional 15% of the Offering at the Offering Price exercisable, in whole or in part, at any time up the closing of the Offering.
The Offering is scheduled to close on December 7, 2017 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the Canadian Securities Exchange.
The Company intends to use the funds for research and development purposes related to its cannabis breathalyzer technologies, working capital and general corporate purposes.
This press release is not an offer or a solicitation of an offer of securities for sale in the United States. The securities described herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold in the United States unless registered under the U.S. Securities Act or unless an exemption from registration is available.
?Not For Distribution To United Stated Newswire Services Or For Dissemination In The United States And Does Not Constitute An Offer In The United States Of The Securities Described Herein.
New Kal Malhi Interview 11/15/2017
https://omny.fm/shows/steele-drex/a-bc-company-has-just-applied-for-a-patent-for-the
Very interesting
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
Further information will be provided in the next report.
Looks like Patriot one got their FCC approval.
https://apps.fcc.gov/oetcf/tcb/reports/Tcb731GrantForm.cfm?mode=COPY&RequestTimeout=500&tcb_code=&application_id=wIhGh0X4buvPsBU6o3xlYQ%3D%3D&fcc_id=2ALZTCMR
We're halted!!!
The B.C. Securities Commission is looking to question a Burnaby man about trading in two listings, Newgen Biopharma Corp. and Breathtec Biomedical Inc. The regulator says that it is investigating some unspecified activity with those companies and is looking closely at Vancouver brokerage Mackie Research Capital Corp. The investigation has led to the Burnaby man, who is named Harish Tak.
The BCSC's petition also states that the regulator is looking into trading and a distribution of securities with Breathtec Biomedical, which trades on the Canadian Securities Exchange.
SENGEX Partners with Patriot One Technologies at ASIS International 2017 Security Symposium
http://www.prweb.com/releases/2017/09/prweb14692926.htm
who cares about a $ 15 cartridge once in a while. just do some math on how many cartridges will be needed. not a major issue!
On June 5, 2017, the Company entered into a corporate research agreement with a non-related party for services to be provided from March 30, 2017 to December 1, 2017 for consideration of $40,204, payable upon full execution of the agreement.
My opinion is you must not read the Cannabix press releases.
Quote from 10/19/16:
Cannabix scientists are formulating a scientific protocol to conduct live THC breath testing using the Beta 2.0 Cannabix Marijuana Breathalyzer in the coming weeks. The scientific testing will likely be conducted in Vancouver BC, Canada, where medical marijuana users will be engaged to determine the accuracy of the Beta 2.0 Cannabix Marijuana Breathalyzer to detect both smoked and edible consumption of marijuana in human breath. The results of the scientific tests will be used to prepare submissions for approval of the Cannabix Marijuana Breathalyzer as a court-approved device by the Minister of Justice in Canada and the National Highway and Safety Authority in the United States.
?
The Beta 2.0 prototype has provided excellent sensitivity in lab testing and will be utilized to conduct scientific studies with live marijuana users (smokers and edible consumers) to test the device for its accuracy and sensitivity using a controlled scientific testing protocol. The results of the scientific test will be used to prepare submissions for approval of the Cannabix Marijuana Breathalyzer as a court-approved device by the Minister of Justice in Canada and the National Highway Traffic Safety Administration (NHTSA) in the United States.
Cannabix Technologies is working to develop a rigorous trial with expedited ethics approval to begin detailed scientific trial testing of the Cannabix Marijuana Breathalyzer
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to announce that Dr. David Hasman has joined its scientific team to initiate trials in Vancouver, British Columbia. Dr. David Hasman is with Forensic Science and Technology at the British Columbia Institute of Technology (BCIT) and has been providing his expertise in the LC/MS/MS method for fentanyl and analogues for the B.C. Provincial Toxicology Centre in Vancouver.
The addition of Dr. Hasman to our Florida-Vancouver scientific team, will broaden our testing capabilities in Vancouver with human subjects using the Cannabix Marijuana Breathalyzer Beta prototype.
Cannabix has been developing its FAIMS based Cannabix Marijuana Breathalyzer for the detection of THC through exhaled breath and continues testing its devices in British Columbia and Florida for sensitivity and consistency of results for Evidential Breath testing purposes.
isolated thc is already in the breath of the subject. in that sense nothing has to be "broken down". when you then measure that thc you have what you have been looking for. cannabix just measures some additional ingredients in the breath of a subject which is nice but wont effect the overall results. hounds device will produce accurate results just like cannabix. but theyll be to market way earlier imo! the writings on the wall here.
Patriot plans to outsource production of CMR-1 to reduce capital expenditures. Patriot has secured statements of work with Macadamian Technologies Inc. (“Macadamian”) for development of the CMR-1 user interface, integration of hardware and commercialization of Patriot’s program algorithm. Copper Mountain Technologies (“Copper Mountain”) has agreed to modify their current vector network analyzer to provide Patriot with a commercially ready beta prototype for use in pilot programs and for initial customers.